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The system for the production and distribution of the United States supply of 
influenza vaccine has experienced disruptions during past influenza seasons.  The process 
of the identification of elements of the influenza vaccine is different each year and must 
be researched and identified each year prior to the influenza season.  The manufacturing 
of the vaccine is a complicated process with a lot of potential problems.  This thesis 
identifies the requirements and constraints of the current manufacturing and distribution 
system including the annual demand and supply.  This information is used to create a 
model based on operational research and operational management theory to develop a 
systematic approach to distribution of the influenza vaccine in a shortage situation.  Two 
different policies are identified for use in a normal influenza season to determine how 
many companies are required to provide a sufficient amount of influenza vaccine with the 
understanding that some of the companies might have manufacturing difficulties.  These 
two policies are the percentage distribution policy and the strict priority distribution 
policy.  The model includes a determination of the number of companies that should be 
available for influenza vaccine production and the amount of vaccine that should be 
ordered from each company to minimize the total cost.  The majority of the influenza 
seasons could be covered by purchasing fewer than 108 million doses, as in the 
percentage distribution policy, making sure that the vaccine dose orders are spread out 
evenly over four companies and distributed evenly by age group percentage, but could be 
reduced to as little as 24.5 million total vaccine doses if necessary with minimal cost and 
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I. INTRODUCTION  
A. BACKGROUND  
Each year there is an estimated 36,000 deaths and 200,000 hospitalizations (CDC, 
July 2005) in the United States due to health problems stemming from the influenza 
virus.  Ninety percent of deaths related to underlying respiratory and circulatory illnesses 
associated with the influenza virus occur among adults older than 65 years of age 
(THOMPSON, 2003).  An untreated flu pandemic could cause widespread sickness and 
death in the United States among all age groups if the country is not ready for the 
possibility.  However, during a normal influenza season panic can still occur if there is a 
shortage of influenza vaccine for distribution.  In 2004, a limited supply of the Flu 
Vaccine developed a panic in the United States.  Mostly the elderly were affected by 
waiting in long lines for the opportunity to receive the influenza vaccine.  An elderly 
woman actually died in line waiting with her husband (AP, 2004).  Chiron Corporation, 
one of the two companies licensed to provide the flu vaccine in the United States at the 
time, had to withdraw 48 million doses of the inactivated vaccine (Fluvirin®) that the 
company expected to deliver in 2004.  That turned out to be half of the 100 million doses 
that were expected to cover the United States population (LA MONTAGNE, 2004).  
Sanofi-Aventis, another authorized United States vaccine manufacturer, was able to 
provide an additional 1.1 million doses of live intranasal vaccine (Flumist) to cover the 
shortage (TREANOR, 2004).  Luckily, the flu season ended up as being mild and the 
limited supply of the vaccine did not appear to cause additional deaths (YEE, 2005).  
However, what steps can be taken to minimize the risks of this type of situation?  
The range of annual demand for flu vaccine is usually 75 to 100 million doses 
(CDC, June 2005).  The type of flu season, from mild to bad, will alter the number of 
shots demanded by the public.  The demand, therefore, can be said to be unknown from 
year to year as can the supply.  A discussion of the problems identified with the influenza 
vaccine supply and demand estimates are detailed in this thesis.  The average amount of 
influenza vaccine ordered, the overall supply chain and the number of United States  
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suppliers were used in the development of a model to determine how many companies 
there should be and the number requested from each company to provide a sufficient 
supply.   
B. PURPOSE  
The purpose of this thesis is to determine the number of doses of influenza 
vaccine required to order from a determined number of manufacturers to prepare for 
influenza vaccine shortages in the future like the shortage in the 2004 flu season.  The 
thesis also looks at how to use the vaccine on hand when a shortage occurs to minimize 
overall cost.  The supply of influenza vaccine is problematic due to the process of 
matching the influenza vaccine components with the expected viruses year to year.  Two 
policies are discussed in this thesis to distribute the influenza vaccine: a strict priority 
distribution policy and a percentage distribution policy.   
A systems engineering approach to the production of the vaccine and the supply 
and demand chain is utilized to develop a model to minimize cost by spreading the 
vaccine production over several companies and focusing the distribution of the vaccine 
produced to specific target age groups.  A detailed review of the current system, the 
manufacturing and distribution processes, and the stakeholders in the system was 
accomplished in Chapter I and Chapter II.  The system was decomposed into separate 
parts to be analyzed.  (HATLEY, 2000)  A look at other models that were developed was 
also accomplished to try to understand the current system.  Starting with the existing 
architecture and current system stakeholder’s requirements and distribution process a 
review of the distribution of vaccination purchases and the distribution policies were 
analyzed to try to develop the policy for the desired optimized outcome, the minimization 
of cost in a shortage situation.  (FORSBERG, 2000)  The process is simply to deliver the 
required vaccine to the customer when required to avoid death.  This becomes difficult 
when there is a limited supply of vaccine.  Understanding the production difficulties, the 
supply process of the vaccine to the distributors and then to the customers, and the 
customer demand are all important aspects of the system.  These were reviewed to 
determine a better way of manufacturing and distributing the vaccine.  This model is 
theoretical and would be difficult to check without the backing of the CDC and all other 
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stakeholders.  For now, we can only complete the system engineering process by utilizing 
the Vaccine Model that was developed and determine the best number of companies and 
the amount to order from each, and the calculated results of distributing the vaccine to 
customers in the two policies developed. 
C. RESEARCH QUESTIONS  
Viewing the recent shortage of the Flu vaccine and the effect on the people in the 
United States led to the questions below.  What were the main reasons for the shortage of 
Flu Vaccine during the 2004-2005 influenza season?  What factors affect the demand and 
supply of the influenza vaccine annually?  What research has already been accomplished 
or is ongoing related to problems associated with the influenza vaccine supply and 
demand estimates and the overall supply chain?  What is the number of United States 
suppliers currently for Influenza Vaccine and how was that number determined?  Is it 
feasible for the United States government to implement a strategy of government supply 
commitments to increase the amount of suppliers and reduce risk of undersupply?  Can a 
reasonable solution to this problem be found by modeling the demand as uncertain and 
the supply as uncertain which develops an adequate Influenza Vaccine required to cover 
the demand?  The ultimate question to be answered is how many influenza shots should 
be ordered from a set number of companies to minimize the effect of a shortage, to cover 
as many customers as possible, and to minimize the overall cost of vaccination orders and 
lost earnings from all deaths.  The number of vaccines ordered should minimize cost 
while covering the demand.  
D. BENEFITS OF THESIS 
This thesis reviews the influenza vaccine production process and distribution and 
related problems associated with the vaccine production, new production technologies, 
and companies that have licenses in the United States to provide the influenza vaccine 
and those companies that are in the process of acquiring the license to do so.  The more 
companies that have a license to produce the vaccine in the United States the easier it will 
be to produce and distribute the vaccine and avoid a shortage.  The question to be 
answered is how many influenza shots should be ordered to avoid a shortage to cover as 
many customers as possible, and to minimize the overall cost of vaccination orders and 
lost earnings from all deaths.  The number of companies used and vaccines ordered 
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should minimize cost while covering the demand.  The death rates of specified age 
groups in the United States are used to develop a model to determine how many 
companies are needed to spread the vaccine purchase to ensure an adequate supply, how 
much vaccine should be ordered from each separate company, and which age groups 
should get the vaccine in order.  The cost of the vaccine doses purchased and the cost of 
each death are minimized to minimize overall cost to the United States.   
The influenza vaccine is a long lead time product.  The current vaccine production 
takes several months so manufacturers must predict the demand and decide how much of 
the vaccine to produce.  If a sufficient number of influenza vaccines are not produced and 
available during a normal severe influenza season or during a pandemic situation, the 
number of deaths related to influenza and complications could reach 500,000 (FOX, 
2005).  Therefore, there is a large penalty for not having the proper amount of vaccine.  
The benefit of the Vaccine Model developed in this thesis would be to minimize the total 
cost of the vaccine purchased while covering as many customers as possible, and to 
minimize the risk of not having enough by distributing the purchase of the vaccine over 
several companies based on economic benefit.  This problem is an example of a newsboy 
model, in which a single product is to be ordered at the beginning of a period and can be 
used only to satisfy demand during that period (NAHMIAS, 2001).  A way of minimizing 
the effect of a shortage would be to order a little extra from multiple suppliers.  This 
thesis identifies a model that can be used to determine the number of companies required 
to provide an adequate supply of the influenza vaccine to minimize the effect of an 
influenza vaccine shortage.  Table 1-1 identifies the companies and vaccine products that 
are currently available in the United States.  Due to the limitations in the amount of 
companies, the developed model does not utilize more companies than four for the 










Table 1-1. Recommended Influenza Vaccines for Different Age Groups 2005 
 
Vaccine 6Mo. 3 Yrs. 4 yrs. 5-49 yrs. >50 Yrs 
FluZone (Sanofi Pasteur, Inc.)  X X X X 
Fluvirin (Chiron)   X X X 
FluMist (MedImmune, Inc.)     X*  
Fluarix (GlaxoSmithKline)    X** X 
*FluMist is only for healthy individuals between 5 and 49 years of age.   
**Fluarix has been approved by the FDA for the 2005-2006 season for adults older 
than 18 years of age. 
 
E. DEADLY INFLUENZA SEASONS 
Influenza A and B are the two types of influenza strains that cause human illness.  
Influenza B viruses are not categorized into subtypes.  Influenza A viruses are 
categorized on the basis of their two surface antigens.  Hemagglutinin (HA) is an 
antigenic glycoprotein found on the surface of the Influenza virus and is responsible for 
binding the virus to the cell that is being infected.  Neuraminidase (NA) is an antigenic 
glycoprotein enzyme found on the surface of the Influenza virus.  The three types of 
human influenza viruses are H1N1, H1N2, and H3N2.  Influenza type A viruses are 
constantly changing and this requires the manufacture of a completely new vaccine batch 
each year.   
Every year United States citizens die from infections caused by the influenza 
virus.  Influenza and pneumonia were ranked number seven on the list of causes of deaths 
among the United States population in 2000 (CDC/NCHS, 2002).  Usually, the virus each 
year only affects small children, the elderly, and those with existing medical conditions 
but three times in the last 100 years there has been an Influenza pandemic, or a world-
wide epidemic, which has affected the United States.  These were caused by new 
influenza A virus subtypes that emerged during the 20th Century.  These new viruses 
spread around the world within one year of being detected.  There were several other 
local epidemics that occurred that did not affect the United States. 
Spanish Influenza 
The first to affect the United States was the “Spanish Influenza” in 1918-19.  The 
origin of the 1918-19 pandemic virus is not clear but it is believed to be caused by a type 
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A (H1N1) virus (SNACKEN, 1999).  The Spanish Influenza epidemic caused an 
estimated 22 million deaths around the world according to the CDC.  Over 12,000 deaths 
were reported in Philadelphia alone in September and October of 1918 (LYNCH, 1998).  
The disease caused a panic in Philadelphia because it hit healthy young adults.  Half of 
the reported deaths were young healthy adults.  Influenza A (H1N1) viruses still circulate 
today after being introduced again into the human population in the 1970s.  In 1918, the 
influenza was helped by troop movements around Europe and the United States.   
1. Asian Influenza 
In 1957-58 there was an influenza pandemic called the “Asian Flu”.  The Asian 
influenza was caused by an influenza A (H2N2) type virus (SNACKEN, 1999).  This 
virus was first identified in China in February of 1957 and spread to the United States in 
the summer of 1957.  An estimated 1 million people died worldwide of the Asian 
influenza, 70,000 in the United States.  A worldwide scare occurred in April of 2005 
when this influenza virus strain was mistakenly sent out to 3,747 laboratories in 18 
countries as part of their certification process.  All parties were asked to destroy the virus 
upon receipt (CIDRAP, 2005). 
2. Hong Kong Influenza 
The “Hong Kong Flu” occurred in 1968-69 and was caused by an A (H3N2) type 
virus (SNACKEN, 1999).  It is estimated that 750,000 people worldwide died of the virus 
and 34,000 of those deaths occurred in the United States.  Influenza A (H3N2) viruses  
still circulate today.  Both the 1957-58 and 1968-69 pandemics were known to be caused 
by viruses containing a combination of genes from a human influenza virus and an avian 
influenza virus. 
3. Avian Influenza 
The latest recorded multiple deaths resulted from the Avian Influenza A (H5N1) 
in China, Indonesia, Thailand, Vietnam, and Turkey with over 60 reported human deaths 
and 140 total cases.  So far, this strain has not produced human to human infection.  
Another Chicken Flu or Bird Flu in Honk Kong, strain A (H5N1), in 1997 resulted in 18 
confirmed human cases and 6 deaths (SNACKEN, 1999).  
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F. VACCINE DEVELOPMENT AND PRODUCTION  
1. Exact Influenza Vaccine Determination 
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) 
of the Food and Drug Administration (FDA) meet each year to determine the formulation 
of the influenza vaccine in the United States for that year.  The surveillance data is 
collected in January and February.  The formulation for the vaccine is then agreed to by 
the committee around March based on observations conducted and the previous year’s 
vaccine contents.  The recommendations are based on antigenic analysis of recently 
isolated influenza viruses.  Post–vaccination serologic studies are also used to develop 
the vaccine  (MEADOWS, 2004).  For example, the 2005 influenza vaccine includes two 
viruses that were used in 2004 (A/New Caledonia/20/99 (H1N1)-like and 
B/Shanghi/361/2002-like), and one new virus identified for this year 
(A/California/7/2004 (H3N2-like)).  This formulation was agreed to in February 2005. 
Each year after the virus strains are chosen by the VRBPAC, the task is then to 
develop the process to grow the strains in embryonated chicken eggs efficiently.  In the 
2003-2004 influenza season there were difficulties in the production of a certain strain of 
influenza virus, the H3N2 influenza A/Fujian/411/02, which was chosen to be used in the 
vaccine to combat the A/Fujian/411/02-like strain that was circulating that season.  It was 
found that increasing the HA receptor-binding activity, balancing the HA and NA 
activities, helped increase production (LU, 2005).  
2. Death Rates as a Product of Influenza Vaccine Supply and 
Distribution  
Influenza vaccine effectiveness depends on the age and the health, or immune 
status, of the patient being vaccinated.  It also depends heavily on the match of the strains 
of the virus chosen for the vaccine for that year.  The vaccine will be more effective if the 
strains used in the vaccine matches what is currently circulating in the United States.   
The vaccine has been found to be 70% to 90% effective in preventing infection in 
healthy adults under 65 and 30% to 40% effective in preventing infection in adults over 
65 based on the National Foundation for Infectious Disease reports (NFID, 2004)  
(ACPTF, 1994).  The American Medical Directors Association (AMDA) reports that 
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generally the influenza vaccine is 50% to 60% effective in preventing influenza related 
hospitalization among those that are 65 and older, and 80% effective in preventing 
influenza related death among those that are 65 and older.  These numbers were based on 
64 different studies (AMDA, 2005). 
3. Potential Influenza Vaccine Suppliers  
There are several companies in Europe and Asia that could be given a license to 
manufacture and distribute the influenza vaccine.  The questions that have to be answered 
are; what is the current process that the FDA uses to qualify these companies and how 
much would the process cost?  This should include a minimum order guaranteed by the 
government if there are not a sufficient number of companies identified with current 
licenses to manufacture and distribute the influenza vaccine in any given influenza 
season.  The process could not be cost prohibitive.  It would take too long to license them 
and get them to start production in an emergency so the list of companies must be 
developed in advance with some of the companies receiving orders to cover the potential 
need.  This would put the United States government in the position of buying an amount 
to at least cover the cost of ramping up the production line on enough companies to have 
a sufficient vaccine supply. 
For the 2005 influenza season there are three companies that have a license to 
provide inactive influenza vaccines in the United States.  The companies are Chiron, 
Sanofi-Pasteur, and GlaxoSmithKline, all of which are in the United Kingdom.  
MedImmune in Gaithersburg, Maryland has developed the LAIV vaccine, which is also 
available for the 2005-2006 influenza season (CDC, November 2005).  GlaxoSmithKline 
received a license under the new FDA fast track approval system in August 2005 to sell 
inactivated vaccine (USA Today, 2005).   
4. Influenza Vaccine Production  
Production is determined by each individual private company that has a license.  
Requests for vaccines are made by health care providers and federal, state, and local 
governments.  Some of the requests come from the Department of Veterans Affairs, long-
term care facilities, acute care hospitals, children’s health care providers, children’s 
vaccine programs, the Department of Defense, and others.  During the crisis in 2004, 
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those who vaccinated the most vulnerable were allowed to have the available doses.  A 
pre-booking process is used to try to eliminate some of the uncertainty of the demand 
(CDC, Key Facts 2005). 
The process of developing and manufacturing the annual influenza vaccine is a 
long one taking approximately six to eight months to complete (WOOD, 1998).  The 
process starts in the autumn of the previous year with the identification of new antigenic 
variants.  The appropriate strains are then chosen to be in the vaccine for the following 
influenza season.  The generation of the appropriate reagents for the antigens is 
accomplished.  Then the vaccine antigens are produced and purified.  The antigens must 
be packaged and distributed.  A yearly batch of influenza vaccine usually can not be used 
the following year and must be continually reformulated to keep pace with antigenic 
changes in the hemagglutinin and neuraminidase proteins of the influenza viruses.  There 
is not time to restart the process.  Therefore, a sufficient amount, usually more than is 
required, must be ordered at the beginning of the year.  Due to the changing Influenza 
Virus there will always be some who are susceptible and die from the infection 
The vaccine is produced in embryonated hen’s eggs and requires the adaptation of 
an appropriate seed virus for high yield growth in the substrate in order to allow efficient 
production (TREANOR, 2004).  Each egg must be hand inspected and hand injected.   
One egg grows 4-5 doses of vaccine.  Millions of eggs are needed for the process.  This 
process produces the inactivated vaccine administered by injection usually into the leg or 
arm muscle.   
The process of using hen’s eggs in the development of the influenza vaccine is 
laborious and ancient.  There is also no room for alteration of the amount of the product 
once the process starts.  The other problem with manufacturing the vaccine is that the 
cost is set and there is no room for negotiation.  The profit margin is reduced making the 
market in the United States less attractive to potential manufacturers.  A number of 
manufacturers left the market leaving only two to produce all the vaccine required in 
2004 (BROWN, 2004). 
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In 2000, there was a disruption in vaccine delivery when two companies had 
trouble with production yields.  There was no contamination.  One of the influenza 
A(H3N2) vaccine components just had lower growth than expected (MMWR, 2000).  In 
the recent history, only Chiron has had a plant closure that would disrupt vaccine 
production.  A disruption risk like the one during the 2004 influenza season is therefore 
very slim.  An act of terrorism would also add a small chance for disruption. 
5. Live Attenuated Influenza Vaccine (LAIV) 
A new version of the influenza vaccine called the Live Attenuated Influenza 
Vaccine (LAIV) was introduced into the market for the 2003 influenza season by 
MedImmune, Inc. of Gaithersburg, Maryland.  MedImmune markets the vaccine under 
the name of Flumist.  A type A and type B master donor virus (MDV) are identified.  
Then, the two MDVs each acquire the cold-adapted, temperature-sensitive, attenuated 
phenotypes through serial passage in viral culture conducted at progressively lower 
temperatures. The vaccine viruses in LAIV are reassortant viruses containing genes from 
these MDVs that confer attenuation, temperature sensitivity, and cold adaptation and 
genes from the recommended contemporary wild-type influenza viruses, encoding the 
surface antigens hemagglutinin (HA) and neuraminidase (NA).  Thus, MDVs provide the 
stably attenuated vehicles for presenting influenza HA and NA antigens, to which the 
protective antibody response is directed, to the immune system (HARPER, 2003).  The 
reassortant vaccine viruses are grown in embryonated hens eggs.  Inactivated influenza 
vaccine contains only killed viruses, but the LAIV contains attenuated viruses still 
capable of replication.  It is licensed in the United States for healthy persons between 5 
and 49 years of age (GERBERDING, 2004).  It has been shown to be ninety percent 
effective or higher for those who received one or two doses (HARPER, 2003).  The 
vaccine is manufactured in hen’s eggs so those who are allergic should not use this type 
of vaccine.  In the case of an emergency the use of this live attenuated virus vaccine will 
free up the inactivated virus for those who are in the higher risk population if the use can 
be approved by the FDA for that use.  However, a limited supply is currently 
manufactured by only one company.  It is also more expensive than the inactive vaccine 
and must be refrigerated at 15o C or colder (HARPER, 2003). 
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LAIV was researched and initially included in the Vaccine Model development.  
This type of vaccine was initially thought to be able to save cost but due to the limited 
application in the specific age groups it turned out not to significantly affect the outcome 
of the model.  The investment into vaccine doses that could be spread out over multiple 
age and risk groups was more effective when purchased.  The first models developed did 
have the option of purchasing a maximum amount of LAIV influenza vaccine 2r .  This 
was limited by the fact that there was only one producer of the vaccine type.  The 
variable 2r  was taken out of the model once it was determined that it was not cost 
effective.  The cost of the LAIV vaccine or r2 is set by MidImmune, Inc., and for the 
2005-2006 influenza season is set at $20.70. LAIV could only supplement two age 
groups effectively, 5-19 Low-risk, and 20-49 Low-risk, and does not significantly change 
lead time for production. 
6. Cell-Based Technologies  
A way to eliminate the use of the egg-based production is to continue to develop 
the new cell-based technology for the influenza virus production.  Cell-based influenza 
vaccines use cells from mammals to grow the viruses used in the vaccines.  Using the 
cell-culture method allows those allergic to eggs the ability to receive the vaccine.  It also 
eliminates the use of the step to adapt the virus to grow in the eggs.  This makes the 
process quicker and provides a much needed surge capacity.  Cells may be frozen and 
then grown quickly in large volumes when required (USD HHC, 2005).  There are three 
cell-based influenza vaccines that are close to receiving regulatory approval in Europe 
and the United States.  One of these was developed by Protein Sciences Corporation, a 
biotechnology company in Meriden, Connecticut.  No live influenza viruses are used.  
The process also eliminates the need for preservatives like thimerosal.  This vaccine 
development could be on the order of weeks instead of months (FLUBLØK PRESS, 
2004). 
In November 2005, President Bush outlined his new strategy to fight potential 
pandemic influenza which included $2.8 billion dollars earmarked to speed the 
development of vaccines (USA Today, 2005). 
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7. Anti-Viral Treatments  
Antiviral drugs for influenza can be used as an addition to the influenza vaccine 
for controlling and preventing influenza. However, anti-viral treatments are not a 
substitute for vaccination.  Antiviral drugs are used to treat influenza type infections 
early.  Four licensed influenza antiviral agents are available in the United States: 
amantadine, rimantadine, zanamivir, and oseltamivir.  Amantadine and rimantadine work 
on the influenza type A.  Zanamivir and oseltamivir work on influenza type A and B. 
In a study conducted in August of 2005, Balicer, Huerta, Davidovitch & Grotto 
analyzed strategies for the use of stockpiled antiviral drugs in the context of a future 
influenza pandemic and the estimated cost benefit ratios.  Balicer et al. estimated the 
health related impact of a pandemic influenza on the Israeli population by using illness, 
hospitalization, and death rates from previous pandemics.  They found that a pandemic 
would result in 2,855 deaths, $55.4 million in health-related costs, and $523.5 million 
overall cost to the economy (≈  0.5% of the Israeli gross domestic product).  Israel is a 
country of 6 million inhabitants  
In the course of their research, three different ways of distribution of prophylaxis 
were identified.  The research concluded that stockpiling of drugs will produce cost 
savings to the government of Israel no matter what strategy is used for their deployment.  
It was also found that the process would return dollars invested by almost a 4 to 1 margin 
(BALICER et al., 2005).  A stockpile of antiviral drugs could also reduce deaths, 
hospitalization, and missed days at work during an influenza pandemic.  
The Avian bird influenza epidemic (H5N1) has forced the United States to start 
stockpiling antiviral drugs, specifically the Tamiflu brand of the oseltamivir antiviral 
drug that seems to work against the H5N1 strain (CBO, 2005).  This is just in case the 
Avian bird influenza virus changes and can be passed from human to human.  This has 
caused Roche Pharmaceutical Company to halt shipment to private companies in the 
United States in October 2005 to so that it would not affect the global supply (AP, 2005).  




two days or less.  It attacks the influenza virus and slows or stops the virus from 
spreading inside the body.  Tamiflu can treat some types of influenza and associated 
illnesses.   
8. Lower Dose Distribution  
Another way to stretch the influenza vaccine in a shortage is to deliver a smaller 
amount of the influenza vaccine to each individual.  Studies have found that one half of 
the standard dose of trivalent influenza vaccine administered by injection into muscle 
produced the same immune response of those given the full dose (TREANOR, 2002).  
Subjects who were older than 60 years of age still saw a good response to the smaller 
dose (LA MONTAGNE, 2004). 
G.  CHAPTER SUMMARY 
The history of recent influenza seasons has shown us that the supply of the 
influenza vaccine is variable and the amount of customers searching for the vaccine also 
varies.  History also teaches us that any one year could be devastating if a pandemic 
develops.  The question to be answered is how many influenza shots should be ordered to 
avoid a shortage assuming a normal influenza season to cover as many customers as 
possible, and to minimize the overall cost of vaccination orders and lost earnings from all 
deaths keeping in mind that a pandemic could occur.  The number of vaccines ordered 
should minimize cost while covering the demand.  After the United States Strategy to 
fight a future pandemic influenza was outlined by President Bush in November of 2005 
he was immediately criticized for only requesting that 20 million doses of the influenza 
vaccine be stockpiled against the current strain of bird flu H5N1.  (USAToday, 2005)  
The critics missed that the cornerstone of the strategy would be to develop the ability to 
produce new vaccines quicker.  Until the companies that provide the influenza vaccine 
have the ability to produce the vaccine at a much more rapid pace hard choices have to be 
made in terms of who gets the vaccine when there is a limited supply.  During a normal 
influenza season and also during a pandemic situation a number of people will die no 
matter how much vaccine is produced and distributed.  However, lives can be saved by 




appropriately.  Until the time that we can produce the influenza vaccine with a quicker 
response time, it is important to understand the production and distribution process 




II. VACCINE SUPPLY AND DEMAND 
A. INTRODUCTION 
The problem of influenza vaccine production and distribution involves several 
complex issues.  Understanding the supply and demand chain for the influenza vaccine is 
helpful in developing an optimized model for ordering the correct amount of vaccine 
each year.  (FORSBERG, 2000)  The uncertainty in production amounts, the uncertainty 
in customer demand, and the supply and demand chain all add to the problem of getting 
the influenza vaccine to where it is needed each year.  The architecture of the influenza 
vaccine distribution system, including inflow and outflow requirements, is analyzed in 
this thesis by utilizing the rational method (MAIER, 2002).  Mathematical principles, 
equations, and estimated costs associated with potential deaths are utilized to develop an 
optimized solution.    
B.   SUPPLY 
The CBO identified several problems in the influenza vaccine supply chain (CBO, 
2005).  The lengthy egg-based manufacturing process means that production cannot be 
scaled up.  Demand for the vaccine each year varies and can depend on outside factors 
like the severity of the previous year and media coverage.  Demand for flu vaccine is 
variable and cannot be stored from one flu season to another.  The manufacturing process 
is prone to contamination.  The government accounts for less than 20% of the market for 
the influenza vaccine.  Few manufacturers of influenza vaccine serve the United States 
because of the problems identified above (CBO, 2005). 
1. Individual Company Reliability History 
Each individual company has had manufacturing problems that have either 
slowed production or resulted in lost batches of vaccine due to contamination.  Some 
have had to close their plant for FDA recertification after contamination problems.  There 
have been problems in three of the last five years resulting in delays in the number of 




2. Production Requests 
The United States market is by far the largest demand of influenza vaccine for the 
world’s producers.  The United States population is around 300 million (U.S. Census 
Bureau, International Data Base, 4/26/05) which is larger than the population of the 
whole of the European Union and 10 times greater than Canada.  The target supply for 
the United States is somewhere between 68 million and 99 million doses of the influenza 
vaccine (CDC, June 2005). 
3. Company Response to Orders 
The number of influenza vaccine doses produced in any given year is limited by 
the capacity of the production facilities, the availability of eggs used for the production, 
and the yield of influenza virus from each egg.  All three of those variables can be easily 
disrupted.  Private companies are required to plan the amount of vaccine they will 
produce well in advance.  Any disruption of the production schedule may lead to a delay 
in the availability of the vaccine and result in a customer relation nightmare.  The 
manufacturing process is currently very rigid and does not allow much room for error in 
ordering.  When the influenza strains are identified and the formulation is complete the 
orders must be placed or there will not be enough vaccine when it is needed.  A 
significant part of the problem is the liability concerns.  Financial disincentives and 
government regulations have caused a number of companies to leave the vaccine market.  
In 1957 there were 26 companies that manufactured the influenza vaccine.  There were 
12 companies 30 years ago that manufactured vaccine.  Back in 1999 there were four.  
Now, we are lucky to have the three that manufacture inactive influenza vaccine and one 
that manufactures the LAIV vaccine.  The demand is also problematic and fluctuates 
based upon the type of influenza season.  Vaccines are not viewed as profitable to 
companies because the market is limited in comparison to the general drug market.  They 
are also tough to develop due to the fact that they change every year. 
C. DEMAND 
1. Normal Season Demand 
In a normal influenza season the demand in the United States for the influenza 
vaccine is usually 75 to 100 million doses depending on the severity of the season (CDC, 
June 2005).  In a pandemic situation that number would at least double to 180 million.  
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The amount of 185 million comes up frequently as the number of vaccine doses that the 
CDC would like to have on hand or at their disposal during the regular influenza season 
(CLARK, 2005).  This number would allow the vaccination of all the elderly, infants, and 
health care workers as well as those in all categories who request it. 
The influenza vaccine market would be considered a small market to most large 
pharmaceutical companies.  Total global market sales are around $6 billion dollars for the 
influenza vaccine.  That is small compared to global sales of drugs which are $340 
billion.  The combination of the demand fluctuation, the limited market, and the potential 
for manufacturing difficulties makes the vaccine market very risky. 
2. Demand Fluctuations 
The demand for the vaccine fluctuates from year to year.  The most influenza 
shots ordered prior to 2005 was 83 million (CLARKE, 2005).  In 2004, only 57 million 
doses were eventually distributed.  In 2005, the estimate for vaccination production with 
production from three companies will be from 71 million to 97 million doses (CDC, 
September 2005).  Table 2-1 identifies the amount of vaccine produced and sold for each 
year starting from 1999.  Some years there is not enough demand and the vaccine goes 
unsold.  When there is a shortage as in 2004-2005 healthy individuals refrain from the 
vaccine which can result again in unused vaccine.  With the price set by the government, 
it can not be raised to take into account the higher risk in the market.  This potentially 
drives companies out of the vaccine production business.  There should be a price and 
quantity curve, which is not there if the government sets the price of the vaccine like a 














Table 2-1. Influenza Vaccine Production and Demand 
 
Year Production (million)* Over/Under (million) 
1999-2000 77 3** (MMWR, 2000) 
2000-2001 75 <1 
2001-2002 87 8** (CDC, 2003) 
2002-2003 79 <1 
2003-2004 87 <1 
2004-2005  60 3*** (BECKER, 2005) 
2005-2006    68-99 - 
*Production numbers taken from CDC Influenza Vaccine Bulletins for the corresponding 
years.   
**Production not actually used.  
***Estimated unused due to healthy persons refraining from the vaccine. 
 
D. DISTRIBUTION 
The influenza vaccine system for the United States will be identified as comprised 
of the Government and Heath Care industry that requests the vaccines for patients and the 
companies that manufacture the vaccine.  In the middle of the two is the distribution 
process which includes private distribution companies.  These private distribution 
companies search out vaccine supplies after all the direct orders have been purchased 
through the manufacturers and act as a clearinghouse for any vaccine remaining at the 
manufacturing facilities.  The amounts a purchaser pays may differ depending upon such 
variables as the quantities purchased, contractual arrangements, and source of purchase.  
The Congressional Budget Office identified the distribution process as inadequate (CBO, 
2005). 
1. Private Distributors 
Private companies purchase the vaccine to either resale or to keep the doses for 
their own use.  This results in many instances in localized shortages.  Including the 
companies that manufacture the vaccine there are 27 private influenza vaccine 
distributors listed on the Health Industry Distributors Association website where doses of 
the vaccine can be purchased.  The CDC recommends that several potential vaccine 
suppliers should be researched to find the vaccine. 
2. Government 
Government entities including state and local federal immunization grantees and 
county and city health departments directly order the vaccine and must make a good 
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estimate of their requirements for the vaccine well in advance of the influenza season.  
They can order directly from the manufacturer prior to the influenza season.  Usually that 
pre-booking activity closes around the beginning of June prior to the influenza season.  
After the season is underway private distributors are used to deliver any additional 
vaccine doses that are available.  Only 20% of the vaccine is ordered by the United States 
Government and therefore, the Government has little say in how the vaccine is distributed 
and used.   
3. Heath Care Providers 
Health care providers must make a good estimate of their requirements for the 
vaccine as well.  Physicians with practices, hospitals, nursing homes, and pediatric care 
facilities all have to provide their requirements so that enough vaccine will be produced. 
80% of the orders are sent to private institutions.  The CDC recommendations on 
distribution and use of the vaccine to certain high risk groups are only used as 
recommendations.  It is up to the heath care provider to determine who receives the 
influenza vaccine.  
4. Distribution Problems 
The United States has experienced a disruption in the manufacture or distribution 
of inactivated influenza vaccine during three of the last five influenza seasons (MMWR, 
2005).  During the 2000-2001 influenza season there was a shortage of the influenza 
vaccine due to the fact that production yields of the influenza type A (H3N2) strain were 
lower than expected.  There were also other manufacturing problems at two of the 
companies that made the vaccine.  This only delayed the delivery of the vaccine from the 
projected October 2000 to December 2000.  Due to this there were three million doses 
that went unused.  Vaccination efforts were focused on the elderly over 65 and those with 
cardiovascular disease or other illnesses that made them more susceptible to the influenza 
virus.  The problem occurred early in the influenza season so there was a delay of 
delivery of the vaccine but it did not have an overall negative affect. 
The other recent major production difficulty occurred during the 2001-2002 
influenza season.  Twenty-six million doses that were supposed to be delivered by 
October 2001 did not arrive until November and December of that year.  That season saw 
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an 8 million vaccine overproduction due to the late arrival of the vaccine.  At the end of 
the influenza season, there were still vaccines not sold.  Only 79 million doses of the 
vaccine were used (CDC, 2003) when 87 million were produced (CDC, 2001). 
The changing amount of vaccine doses that are used, the vaccine manufacturing 
process, and the government approval process affect the system.  There are several 
companies that manufacture and distribute the vaccine in Europe that could provide the 
vaccine in the Untied States if they go through the approval process.  The approval 
process must be identified as a roadblock to increasing the number of companies 
available to manufacture and provide influenza vaccine in the United States.  Only one 
company came into the United States vaccine market in 2005.   
Companies respond to orders placed prior to the start of the influenza season and 
additional orders during the season until their supply runs out.  Currently, under the 
system as it is set up, there is no means of being flexible to additional requests for a more 
severe season or a pandemic situation.  Therefore, there must be several companies in 
place before the influenza season that can produce the amounts required. 
5. Free Market versus Uniform Distribution in Other Countries 
The United States uses the free market to purchase and distribute the influenza 
vaccine just like any other product.  The supply for each influenza season is based on 
demand from previous years and the pre-booking orders that are provide by the 
government vaccine distributors and heath care workers.  Private companies who are 
licensed to manufacture the vaccine determine first if it will be cost effective to 
manufacture the vaccine and then how much they will produce.  As long as the egg based 
system is used to develop the vaccine a steady demand known in advance is necessary to 
drive production in a free market.  Once the vaccine is produced then it falls into the 
distribution system which should be monitored to ensure that the vaccine gets to those 
who need it.  In some instances the big purchaser seems to be favored over the small 
purchaser and often the ability to shift vaccine from areas with an over supply to areas 
with local shortages has been difficult due to many suppliers and no single clearinghouse 
or distribution point.  
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Canada is the only country that vaccinates more of a percentage of its population 
than the United States.  This is accomplished through programs implemented by the 
Canadian Coalition for Immunization Awareness & Promotion (CCIAP).  The goal of the 
CCIAP is to help ensure that all Canadians are aware of the importance of immunization 
and that all Canadians are properly immunized.  Each province in Canada has taken the 
influenza vaccine program as a high priority.  In Ontario, the “Ontario Experiment” is 
under way with the Canadian Government offering the influenza vaccine free to all who 
want it.  In three provinces in Canada, including Ontario, the vaccine is offered free of 
charge to all customers.  It is also offered free to the high-risk groups in the other 
provinces with an overall total vaccination rate for Canada of around 27% (CBC, 2005). 
With the smaller amount of total population, around 33 million, it is easier for Canada to 
distribute the vaccine. 
Dr. Julie Gerberding, (CDC, 2005) of the CDC in a press conference in 
November, 2005 admitted that, “the vast majority of flu vaccine is in the private sector 
and we have very little capacity to move vaccine around. So, what we are doing is 
preparing our own stockpile of vaccine, getting about 800,000 doses of vaccine from 
Chiron at the end of November (2005), and we'll use those doses to help offset shortages 
in communities where there is no one with vaccine available”.  In October 2004, when 
there was a severe shortage of vaccine no one single entity knew how much was 
available, where it was, and who needed it most.  A simple information-sharing system 
was developed but that did not help the problem of local officials deciding person by 
person who should get the vaccine.  Distribution and tracking of the vaccine could be 
vastly improved if each state or region would develop a single entry point and a better 
tracking system to ensure that the vaccine gets to where it is needed. 
6. Simplified Model 
A simplified distribution system is used to model the manufacturing, distribution, 
and use of the influenza vaccine.  For the model, each company is considered to have one 
batch of vaccine that they produce.  This makes the vaccine for that company good or bad 
and not partially good or bad.  Chances are that if there is a manufacturing problem or 
contamination it will shut down the plant.  A delay will be modeled as a good batch that 
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arrives in time to utilize.  The model also simplifies the distribution to eliminate the 
private distributors and focuses on the manufacturer to health care provider line.  The 
assumption is that the vaccine will find the paying customer if there is still vaccine left in 
the market. 
E. CHAPTER SUMMARY 
The system for the production of the United States supply of flu vaccine has been 
affected over the last few years by supply shortages.  Each year influenza vaccine 
production is a complex process with little room for error.  The process of vaccine 
component production and filling a vaccine request can take up to nine months.  The 
companies that can sell the influenza vaccine in the United States are limited.  The 
demand is up and down based on a mild or severe year for influenza infections.  
Sometimes the companies sell out of vaccine, other years they go unsold adding 
additional risk to a small overall market.  The difficult manufacturing process, the limited 
time to identify and manufacture the product, government regulations and license 
requirements all lead to a high risk situation for any commercial company that 
manufactures the influenza vaccine.  The problems in production, the difficulties in the 
distribution of the vaccine, and the demand uncertainty were reviewing the current 
system architecture and were taken into account when developing the new model to 
distribute the influenza vaccine.  The next chapter introduces a new Vaccine Model 
developed as part of this thesis research to combat the problem of purchasing and 
distributing incorrect amounts of influenza vaccine each year.  
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III. VACCINE MODEL 
A. VACCINE MODEL INTRODUCTION 
This chapter introduces the Vaccine Model developed as part of this thesis 
research.  The Vaccine Model can be used to identify the correct number of vaccines to 
be ordered from each company.  The vaccine order quantities are based on the number of 
companies available for the production of the influenza vaccine and divided equally 
between those companies to minimize overall cost.  The Vaccine Model determines the 
number of customers based on the population of the United States and their age, and then 
determines how many companies are needed to spread out the purchase to ensure that 
enough is available for the determined amount of customers.  Finally, the Vaccine Model 
then determines which age groups should receive the vaccinations first to minimize total 
cost.  A goal of this thesis research is to help minimize cost while providing sufficient 
vaccinations to those who request it.  
The Vaccine Model calculations are implemented in Excel and calculations are 
produced using the Frontline’s Solver in Microsoft Excel.  The total cost of the vaccine 
program cell is minimized.  The total cost includes the cost of the vaccine purchased and 
the cost of the deaths associated with the influenza virus.  Two policies were used in the 
distribution of the vaccine.  One policy uses a strict priority that was developed for the 
distribution of the vaccine.  The other policy would be to distribute the vaccine by 
population percentage as the customers came to receive the vaccine.  The Vaccine Model 
is also used to look at a pandemic situation in which more than usual percentages would 
request a vaccine in each age group identified.   
The Vaccine Model is primarily developed on the basis of the number of 
customers.  The number of potential customers is based on the population of the United 
States and is set at 80,679,143 as a default.  The number is developed by dividing the 
total population of the United States into age groups and using the past percentages of 
vaccination in each age group to determine the potential total customers.  This number 
can be changed by changing the observed percentage of each age group that requests a 
vaccine.   
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B. VACCINE MODEL DEVELOPMENT AND DISTRIBUTION POLICIES 
The Vaccine Model is primarily developed on the basis of the number of 
customers.  Customers are defined for the purpose of the model as the total number of 
United States citizens that request a vaccine.  Non-customers are defined as the United 
States citizens that do not actively seek a vaccination during the influenza season.  The 
customers are divided into age groups and are placed into high-risk or a low-risk 
category.  On any given influenza season the number of customers requesting vaccination 
ranges from 70 to 90 million depending on the severity of the season.  In a pandemic 
situation that number would at least double to 180 million.  The amount of 185 million 
comes up frequently as the number that the CDC would like to have on hand or at their 
disposal during the regular influenza season (CLARK, 2005).  This number would allow 
the vaccination of all the elderly, infants, and health care workers as well as those in all 
categories who request it.   
The Vaccine Model calculations are used to determine how many companies are 
required and how many vaccine doses from each company should be ordered to have an 
adequate supply of vaccine on hand during the influenza season.  It is important to get a 
large amount of the vaccine out to the public as early as possible due to the tapering off 
of customer demand because the influenza season usually peaks in February (YEE, 
2005).  The mortality rate also peaks by the end of February (EURO, 2001).  The hope is 
that the free market and the increase in the fair market price of the vaccine agreed upon 
by the United States Government will entice private companies to invest in the market 
(CDC, June 2005).  The total United States population data was gathered from United 
States Census (2000).  The Vaccine Model is set up using the indices, parameters, 
decision variables, constraints, and objective function below. 
The indices used in the Vaccine Model are: 
i = Customer category (i=1, 2… 10) 
j = Customer category (j=1, 2… (i-1)) 
n = Number of companies with a bad vaccine batch (n=1, 2, 3, 4) 
N = Number of companies total (N=1, 2, 3, 4) 




The parameters used in the Vaccine Model are: 
A = Influenza virus attack rate for all people in all age groups 
CostF = Cost of those that die without ever looking for a vaccine 
Ci = Cost of death based on age for each customer category  
DnNR = Cost of all vaccinated and unvaccinated customer deaths 
f1 = Cost of the total vaccine purchased  
f2 = Cost of all those that die that requested a vaccine but did not get one 
f3 = Cost of all those that die that requested a vaccine and were given a vaccine  
n = Number of companies with a bad vaccine batch 
PnN = Probability of contamination of a company vaccine batch 
Qi = Probability of death for unvaccinated customers 
Qi’= Probability of death for vaccinated customers 
QXi = fraction of the unvaccinated, attacked population in age group i that dies 
QXi’ = fraction of the vaccinated, attacked population in age group i that dies  
XinNR = Total number of customers in group i 
XjnNR = Total number of customers in group j already vaccinated (strict priority) 
T = Total number of customers in the United States 
TotalCost = Total cost of all vaccine purchased and all deaths 
V = Cost per inactivated influenza vaccine 
YinNR = Total number of customers vaccinated in group i 
The decision variables used in the Vaccine Model are: 
N = Number of companies required to minimize cost 
R = Number of vaccine to be purchased to minimize cost 
The equation that is minimized is: 
FCostRNnfRNnfRNnfETotalCost +++= )),,(),,(),,(( 321       Equation 1 
Subject to the constraints: 
R ≥ 0, N ≥ 0             Equation 2 
The Decision variables for the Vaccine Model are the total inactivated vaccine 
purchased R, and the total number of companies to purchase the vaccine from N.  The 
variable n is the number of companies that develop a bad batch of vaccine that can not be 
used.  If the vaccine can not be used it will not be delivered, and therefore, not paid for.  
The N value must be smaller or equal to the number of companies that currently have a 
license to sell vaccine in the United States market.    
Parameters for the Vaccine Model include the cost per inactivated influenza 
vaccine dose V, the total number of customers T, which is the sum of the customer totals 
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of each age subgroup XinNR, the number of companies that fail to produce useable vaccine 
n from a total number of N companies, the probability of contamination with each order 
of vaccine P (see Table 3-4), the probability of death given a vaccine shot Qi’, and the 
probability of death given no shot for low risk and high risk customers Qi, and the total 
number of customers receiving a vaccine YinNR.  The percentages of each age group in the 
general United States population and the percentage of those in each age group 
requesting vaccination on any given year divided by high and low risk groups is used to 
determine the number of customers that will require an influenza vaccine.  The Vaccine 
Model is primarily developed on the basis of the number of customers.  The number of 
potential customers T is based on the population of the United States and is set at 
80,679,143 as a default.  This number is developed by dividing the total population of the 
United States into age groups and using the past percentages of vaccination in each age 
group to determine the potential total customers.  This number can be changed by 
changing the observed percentage of each age group that requests a vaccine.  The cost of 
the inactivated influenza vaccine V as set by Medicare’s 2005 Physician Fee Schedule 
was $18.31 (CDC, 2005). 
The question to be answered is how many influenza shots should be ordered from 
a set number of companies to minimize the effect of a shortage, to cover as many 
customers as possible, and to minimize the overall cost of vaccination orders and lost 
earnings from all deaths.  The number of vaccines ordered should minimize cost while 
covering the demand.  Until the companies that provide the influenza vaccine have the 
ability to produce the vaccine at a much more rapid pace hard choices have to be made in 
terms of who gets the vaccine when there is a limited supply.  During a normal influenza 
season and also during a pandemic situation a number of people will die no matter how 
much vaccine is produced and distributed.  However, by having the ability to produce the 
vaccine required quickly and distributing it appropriately lives can be saved and the 
overall death toll and cost for the United States can be minimized.  These two objectives, 
minimizing the death toll and minimizing the overall cost to the country, will contradict 
each other.  With an endless amount of vaccine the amount of deaths will be limited to a  
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fraction of those who do and do not search out a vaccine.  With no funds and no program 
to distribute the vaccine there will be many more deaths that will cost the country and 
individual families lost providers and wages.   
Two policies are looked at in terms of purchasing the vaccine doses.  These 
policies determine which customers receive the vaccine doses available in the Vaccine 
Model.  The first policy is to vaccinate the population as they arrive based on the 
percentage that request vaccination.  This is a real world scenario and would be the 
normal way that the vaccine is distributed.  Every year there are target groups by the 
CDC to receive the vaccine but the majority of the vaccine is distributed to the customers 
that search for it.  The second policy provides the vaccination to only those in high risk 
groups first, using the required amount to cover all high risk groups, then to distribute to 
the lower risk groups if there is any remaining.  This type of strict priority policy could be 
used in a shortage situation to minimize deaths due to an unforeseen shortage. 
C. VACCINE MODEL AGE CATEGORIES AND PRIORITY 
Age categories have been identified for use in modeling affects of influenza.  
Meltzer (1999) identified 0-19 years, 20-64 years, and 65+ years.  These categories were 
assigned present value earnings lost by Meltzer, as well as illness and hospitalization 
costs.   
Table 3-1 identifies each age category and the percentage of each age category in 
the total population of the United States (U.S. CENSUS, 2000).  The percentage of high-
risk and low-risk customers from each age group based upon the United States population 
is shown in Table 3-2.  This table is based on the past percentages of customers (i.e. 
persons looking for an influenza vaccine).  The average number of persons in each age 
category requesting a vaccination varies but is estimated by past percentages.  The 
vaccination percentage has been significantly improved along with other childhood 
disease vaccinations for young children at 81% for 2003-2004 (FOX, 2005).  The 
percentage of adults 65 years and older that are vaccinated ranged from 40% to 70% in 
1999, but has increased to 60% to 70% in 2005. (MELTZER, 1999; and ZWILLICH, 
2005). 
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For each age category and risk level in Table 3.2, the percentage of those in each 
age group who usually request vaccination in the United States was multiplied by the 
number of persons in each category to determine the potential number of customers XinNR 
that would show up at a distribution point for a vaccination.    
 
Table 3-1. Age Categories and Related United States Population 
 
Age US Pop (Mil) US Population Percentage 
0-4 19.18 6.82% 
5-19 61.30 21.78% 
20-49 124.09 44.10% 
50-64 41.86 14.87% 
65+ 34.99 12.43% 
 
The health impact of individual seasons can vary widely on the basis of the size of 
the susceptible population, the prevalence of influenza infections, the type and strain of 
the annual viruses introduced into the population during the influenza season, and the 
match between the current virus strains and the strains used in the vaccinations.  The 
Vaccine Model estimates how many customers in each group will likely request a 
vaccine based on population of the United States and the population of each age group.   
Two policies for the distribution priority of the vaccine are used in the Vaccine 
Model.  The strict priority distribution policy uses a rigid priority to distribute the 
influenza vaccine.  If the higher risk groups are targeted first in a set strict priority, and 
the distribution is limited to those groups only, you can limit the deaths associated with a 
shortage of the vaccine and overall cost.  A study of the percentage of persons in each 
category, the potential for death, and the cost of death associated with each age category 
was accomplished to develop a priority of vaccination.  This priority of vaccination, 
based on the calculated probabilities of death, is identified in Table 3-2.  Additional 
information on the probabilities of death is provided in the next section and in Table 3-3.  
The vaccination priority in Table 3-2 was used strictly in the Vaccine Model to distribute 




distribution could be used in an influenza vaccine shortage or pandemic situation in 
which there was not enough time to produce additional vaccine to cover the increased 
demand.   
The percentage distribution policy provides the vaccine to customers as they 
request it.  In a normal influenza season, customers come to request vaccine based on 
their age categories and risk group.  Each age and risk group has a percentage that 
searches for a vaccine as identified in Table 3-2.  The vaccine is then distributed based on 
the percentage of customers that request a vaccine.  No one group is completely 
vaccinated but the majority of all high risk groups are vaccinated.   
 



















1 0-4 Years Old 
HR 
6.4% 1.23 81% (Fox, 2005) .994 
2 5-19 Years 
Old HR 
6.4% 3.92 24% (Zwillich, 2005) 14.542 
3 20-49 Years 
Old HR 
14.4% 17.87 24% (Zwillich, 2005) .942 
4 50-64 Years 
Old HR 
14.4% 6.03 37% (Zwillich, 2005) 8.607 
5 65+ Years Old 
HR 
40.0% 13.99 70% (Fox, 2005) 4.289 
6 0-4 Years Old 
LR 
93.6% 17.95 81% (Fox, 2005) 15.933 
7 5-19 Years 
Old LR 
93.6% 57.38 15% (MMWR, 2005) 2.230 
8 20-49 Years 
Old LR 
85.6% 106.22 15% (MMWR, 2005) 10.750 
9 50-64 Years 
Old LR 
85.6% 35.83 30% (MMWR, 2005) 9.797 
10 65+ Years Old 
LR 
60.0% 20.99 60% (MMWR, 2005) 12.596 
Total   281.42  80.68 
 
D. INFLUENZA VIRUS ATTACK AND DEATH RATES 
QXi’ is the fraction of the vaccinated, attacked population in age group i that dies 
due to the influenza virus.  QXi is the fraction of unvaccinated, attacked population rate of 
deaths due to the influenza virus.  The Attack Rate A is the attack rate in the United 
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States for all people in all age groups and is assumed to be homogeneous across all age 
groups and risk categories.  The attack rate is defined as the percentage of the United 
States population, customers and non-customers, which will be attacked by the influenza 
virus strain during the influenza season.  In the Vaccine Model, the normal influenza 
season is modeled using a 20% attack rate (MELTZER, 1999; LEE, 2006; GERDIL, 
2003; CBO, 2005).  The attack rate multiplied by the percentage of each population death 
rate if attacked gives the fraction of each age group that dies of the influenza virus.   
The overall death rates used by the Vaccine Model are taken from Meltzer (1999) 
and are considered the upper bound of the expected death rates.  These death rates are 
identified in Table 3-3 and are not homogeneous.   
The effectiveness of the influenza vaccine is a topic for discussion.  The Advisory 
Committee on Immunization Practices (ACIP) stipulates that the effectiveness of the 
inactivated influenza vaccine depends “primarily on the age and immunocompetence of 
the vaccine recipient and the degree of similarity between the viruses in the vaccine and 
those in circulation.”  (MMWR, 2005).  The effectiveness of the vaccine is dependent 
upon the health of the person being vaccinated and the guess made of the influenza 
strains that will be circulated during the influenza season.  Studies have shown that the 
vaccine was 58% to 91% effective in combating illness in children, 22%-54% effective in 
children with one high risk factor, 60%-78% effective in older children with one high risk 
factor, 52%-90% effective in healthy adults younger than 65 (attributed to good or bad 
virus matching), 38% effective with those adults that have one or more high risk factors, 
and 30% - 70% effective with those adults that are older than 65 (MMWR, 2005).  Other 
studies have found less benefit after vaccination.  Taking into account the barriers to 
effectiveness and the past studies completed, an estimation of the vaccine effectiveness 
was developed and used in the Vaccine Model.  The percentage used for vaccination 
effectiveness in the Vaccine Model is 60%.  This assumption can be changed when 
definitive numbers are produced by the CDC.  This is slightly lower than the published 
CDC number of 70% (MMWR, 2005).   
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The customer category is based upon cost per loss of life in that age category 
generated by the Vaccine model explained below in Section F of this chapter.  The cost 
per loss of life is highest for 0-4 and 5-19 high risk age group, and is lowest for the older 
than 65 low risk group.  The customer category rank is shown in Table 3-3. 
The overall death rates for unvaccinated customers Qi is given by Equation 3 
below. 
 
AXiQiQ =              Equation 3 
 
Table 3-3 shows overall death rates for the 10 age and risk groups.   
 
Table 3-3. Age Categories and Death Risk Probabilities 
 







0-4 years  High 7.65 1 .00153 .000459 
0-4 years Low 0.125 6 .000025 .000015 
5-19 yrs.  High 7.65 2 .00153 .000459 
5-19 yrs.  Low 0.125 7 .000025 .000015 
20-49 yrs. High 5.72 3 .001144 .0003432 
20-49 yrs. Low 0.09 8 .000018 .0000108 
50-64 yrs. High 5.72 4 .001144 .0003432 
50-64yrs.   Low 0.09 9 .000018 .0000108 
65+ yrs. High 5.63 5 .001126 .0004504 
65+ yrs. Low 0.54 10 .000108 .0000756 
*Death Rates are taken from Meltzer (1999) per 1,000. 
 
E. COMPANY RATE OF BATCH CONTAMINATION 
An estimate for the probability of contamination is required for the Vaccine 
Model due to the uncertainty of the manufacturing process.  A 10% estimate of batch 
contamination was used.  The probability of contamination with each vaccine order P is 
shown in Table 3-4 for one, two, three, and four companies.  The probability of a good 
batch with each vaccine order would then be (1- P ).  The probability of a bad batch given 
an order is modeled as a binomial distribution where 13P  is the probability that one batch 
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is bad when you order from three companies.  The influenza vaccine production was 
significantly slowed or reduced by contamination or manufacturing problems three times 
between 2001 and 2005.  Therefore, a ten percent probability is a reasonable estimate for 
P.   
 




Contamination     
 PnN 0 1 2 3 4 
1np  0.9 0.1       
2np  0.81 0.18 0.01    
3np  0.729 0.243 0.027 0.001   
4np  0.6561 0.2916 0.0486 0.0036 0.0001 
 
F. VACCINE MODEL DEATH COSTS 
The goal of the Vaccine Model developed for this thesis is to minimize the cost of 
death and the cost of the vaccine used under the current situation of limited resources and 
a time constraint for the production of the vaccine.  The only way to do this is to identify 
an amount of money for each potential life lost and then use that to develop a function 
based on those dollar amounts, and then minimize it based on the amount of deaths using 
a certain amount of vaccine and the cost of the vaccine program itself. 
For each age category, Meltzer (1999) placed a price on the lost wages over a 
lifetime of persons that have died.  The average cost of a death in 1995 US dollars of one 
under 19 was $1,019,536, 20-64 years was $1,045,278, and only $74,146 for someone 65 
years old and older.  The cost of death was estimated in 2006 by Lee at $1.9 million for 
those under 19 years of age, $1.8 million for those 20-64 years of age, and $190,000 for 
those 65 years and older (LEE, 2006).   
Some critics of the vaccine priority list developed by the CDC say that younger 
individuals should be given priority over the elderly for vaccination.  They argue that 
vaccine effectiveness is less for older individuals and younger individuals play an 
important role in the supply chain for food, etc (COWEN, 2005).    
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For the Vaccine Model, the cost of death parameters Ci are estimated at 
$1,000,000 death cost for all persons in customer categories under 65, and $75,000 for all 
persons in customer categories 65 years of age and older.  The focus of this thesis is on 
the cost of death and developing a number of available vaccines so that the right amount 
of vaccine is provided to each age group to reduce potential deaths.  Ci could be 
calculated for each age group resulting in a prorated Ci for all ages which could then be 
inserted into the calculations.  Calculations would be based on annual earnings and work 
histories for low and high risk customer categories.  The use of a prorated Ci would 
greatly increase the utility of the Vaccine Model and is considered for future research.    
G. VACCINE MODEL STRUCTURE 
The Vaccine Model needs to solve the problem of selecting (R, N) to minimize 
the expected value of the cost of the vaccine purchased f1, the cost of those dying after 
they receive a vaccine f2, the cost of those dying that did not receive a vaccination f3 after 
requesting it, and the cost of those dying that never looked for a vaccine, CostF.  Thus, 
the equation to minimize is; 
 
( ( , , ) ( , , ) ( , , ))1 2 3TotalCost E f r n N f r n N f r n N CostF= + + +           Equation 1 
 
The constant FCost  is the cost associated with the non-customers, the population 
that does not seek a vaccination.  This is calculated by multiplying the amount of 
population not seeking a vaccine by the percentage of death for unvaccinated persons.  
FCost  does not have to be added into Equation 1, since it is not affected by the amount 
of vaccine available, but is included here for completeness.    
The variables R and N are constrained to be nonnegative. 
 
 R ≥ 0, N≥0                  Equation 2 
 
Let DnNR be f2+f3, the cost of all customer deaths.  There are XinNR customers in 





inNRinNRiinNRiinNR YXQYQCD ))(()'(               Equation 4 
The first part of Equation 4 is the cost of the vaccinated customers.  The second 
part of Equation 4 is the cost of the customers that were not vaccinated. 
We can now write Equation 1, TotalCost, as the sum of those that do not seek a 
vaccination CostF, the cost of purchasing the vaccine itself, and the cost of the customers 
that seek a vaccination and either receive it and still die or do not have the chance to 














                    Equation 5 
 
The cost of vaccine purchased itself and the cost of the customers that do and do 
not receive a vaccination is calculated in the second part of Equation 5.  The variables R 
and N should be selected to minimize this total cost.   
We will consider two policies for vaccine distribution: A percentage distribution 
policy and a strict distribution policy.  Both distribution policies use the Equations 1 
through 5 above.  The difference in the policies is the way that the vaccine is distributed 
once the number of customers is calculated.  The equations below are used to determine 
how many vaccines there are to distribute and which customers receive them.  











nNRXY           And YinNR ≥ 0              Equation 6 
 
Equation 6 reduces the vaccine available as the customers get them based on a 
strict priority distribution.  Once all the customers in the first highest risk group based on 
their customer category identified in Table 3-2 are covered completely, the vaccine is 
then passed on to the next highest customer category that has customers not yet 
vaccinated.  The amount of vaccine that was purchased )(
N
nNR −  is reduced during 
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each step by the vaccine already used for higher risk groups.  The vaccination of 
customers continues by priority until the limit of )(
N
nNR −  number of vaccines is 
reached.  This limit takes into account the reduction of the vaccine ordered but not 
purchased due to batch contamination. 






−=          When     T
N
nNR <−                      Equation 7 
 
inNRinNR XY =            When    TN
nNR ≥−        Equation 8 
 
The percentage of customers that receive the vaccine for each age and risk 
category are calculated using the percentage of the total customers in each category 
divided by the total number of customers in all categories.  In this manner most 
customers in each category receive the vaccination but all the customers in each category 
are never completely vaccinated.    
H. RECOMMENDATIONS 
Based on the fact that there is no discount for volume, the more companies that 
can spread the vaccination purchases is the best scenario.  For the 2006-2007 influenza 
season the model calculated the number of vaccine doses that were required to minimize 
cost under the assumptions that all inactive vaccine is used appropriately for each age 
group, and the vaccine purchased in the United States can be divided equally into four 
companies.  Using four companies, the purchase of 24,335,875 influenza vaccine doses 
provides an average death total of 44,985 and total cost of $34.6 billion in a normal 
influenza season if a strict priority distribution is used as in Table 4-1, Scenario 1.   
If you had enough vaccine to distribute to all who wanted a dose you could save 




any population comes to purchase one the amount of vaccine needed goes up to 
107,572,140 vaccine doses, which provides a death toll of 43,631 at a cost of $35.5 
billion dollars as in Table 4-2, Scenario 2.   
Chances are, however, that there will not be enough time to manufacture and 
stockpile enough vaccine for the entire United States population.  Therefore it is 
recommended that you aggressively target the vaccine doses to the high risk groups that 
will reduce overall total cost. 
For example, in the best case scenario of all four companies having good batches 
and using the strict priority vaccination policy identified above you need only 24,335,875 
vaccine doses to limit the total deaths to 10,908.  If you distribute 80,679,143 doses to 
cover all the potential customers the death toll will drop to 9,548 deaths.  This is only a 
reduction of 1,360 deaths with an additional 56,343,268 vaccine doses distributed and 
83,236,265 additional vaccine doses purchased.  This suggests that a strict priority for 
vaccination should be considered even during seasons where shortages have not occurred.  
Based on the Vaccine Model calculations and using four companies you would 
order 6,083,967 doses from each of the four companies for the normal scenario utilizing 
the strict priority distribution policy and 52,085,151 from each of the four companies in a 
pandemic situation.  Under the percentage distribution policy all requesting customers 
can be vaccinated and there is not a shortage until more than one company defaults on 
their shipment of vaccine.   
I. RISK ASSESSMENT 
1.   Cost of Life 
The argument can be made that all life no matter what age should be considered 
equal.  Under a shortage condition, a strict priority distribution policy would be used to 
distribute the influenza vaccine.  If the cost of life is changed and made equal for the 
normal influenza season with priority distribution then the total cost of the program 
increases to $45.23 billion from $34.6 billion with an additional 12 million vaccine doses 




outcome and the total expected cost of the program using the priority distribution policy.  
The average number of deaths would be 44,618, which are approximately 300 less than 
using a reduced amount for the cost of life for those 65 and older.  
It will be hard politically to develop a scenario without the possibility of 
vaccinations provided for everyone.  However, it will be impossible to try to purchase a 
vaccine for each individual each year based on each of the potential influenza strains that 
might infect the United States population.  
2.  Cost of Vaccine 
The cost of vaccine on average would be $613.58 million versus $409.05 million 
for the reduced cost of all persons 65 and older.  The cost of the vaccine, cost of each life 
lost, and the total cost of the program must be reviewed to assess the risks and costs that 
the country as a whole are willing to take on to adequately distribute supply of the 
vaccine when required.  The first row in Table 3-5 corresponds to N=1, the second row 
corresponds to N=2, the third row corresponds to N=3, and the fourth row corresponds to 
N=4 with each column corresponding to the number of companies n that result in 
contaminated vaccine batches that cannot be used. 
 
Table 3-5. Scenario A: Normal Influenza Season Cost in Billions, Priority 
Distribution, and Life Cost Equal 
 
Companies Average Cost all Good 1 Bad Batch 2 Bad Batches 3 Bad Batches 4 Bad Batches 
1  $ 46.47 $ 45.22 $ 57.69    
2  $ 45.34 $ 45.22 $ 45.16 $ 57.69   
3  $ 45.33 $ 45.22 $ 45.18 $ 49.15 $ 57.69  
4  $ 45.23 $ 45.22 $ 45.19 $ 45.16 $ 51.20 $ 57.69 
 
J. CHAPTER SUMMARY 
The Vaccine Model can identify the number of vaccine doses to be ordered during 
a normal influenza season and also a pandemic situation.  The investment into vaccine 
doses that could be spread out over multiple age and risk groups was more effective when 
purchased.  A strict priority distribution policy and a percentage distribution policy are 
used to determine the number of companies and the amount of vaccine to purchase from 
each company.  The cost of the vaccine, cost of each life lost, and the total cost of the 
program must be reviewed to assess the risks and costs that the country as a whole are 
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willing to take on to purchase more than required so that an adequate supply of the 
vaccine is available when required.  The use of the Vaccine Model provides insight into 
the supply and distribution of the vaccine to the customers that request it.  In reviewing 
the model results recommendations can be made to avoid unnecessary loss of life and 
cost when the influenza vaccine supply does not match the required demand.  In the best 
case scenario of all four companies having good batches and using the strict priority 
vaccination policy identified above you need only 24,335,875 vaccine doses to limit the 
total deaths to 10,908.  If you distribute 80,679,143 doses to cover all the potential 
customers the death toll will drop to 9,548 deaths.  This is only a reduction of 1,360 
deaths with an additional 56,343,268 vaccine doses distributed and 83,236,265 additional 
vaccine doses purchased.  This suggests that a strict priority for vaccination should be 
considered even during seasons where shortages have not occurred.   
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IV. CONCLUSIONS AND RECOMMENDATIONS  
A. INTRODUCTION 
A systems engineering approach to reviewing the system architecture, including 
the development, manufacturing, distribution, supply and demand of the influenza 
vaccine, was used to develop a Vaccine Model to distribute the influenza vaccine to 
minimize cost.  Research was conducted on the manufacturing process to determine how 
to better manufacture the vaccine, how the vaccine was purchased, distributed to health 
care providers, and then provided to the public.  The vaccine production and distribution 
system was decomposed into its separate parts to be analyzed.  The production of the 
vaccine is difficult and there are several ways being researched to improve that portion of 
the system.  Understanding the supply and demand chain for the influenza vaccine is 
helpful in developing an optimized model for ordering the correct amount of vaccine 
each year.  (FORSBERG, 2000)  The uncertainty in production amounts, the uncertainty 
in customer demand, and the supply and demand chain all add to the problem of getting 
the influenza vaccine to where it is needed each year.  The architecture of the current 
influenza vaccine distribution system is analyzed in this thesis by utilizing the rational 
method (MAIER, 2002).  The system characteristics were identified, the distribution 
system was modeled utilizing its basic elements, and the inflow and outflow requirements 
were identified.  (HATLEY, 2002)  Mathematical principles, equations, and estimated 
costs associated with potential deaths are utilized to develop a solution to the distribution 
of the influenza vaccine.  Two alternative policies were developed to distribute the 
vaccine in the most cost effective way.  The Vaccine Model was used to analyze those 
policies and determine the best way to distribute the vaccine to minimize cost.   The 
development of the vaccine each year, the difficult manufacturing, the supply headaches, 
and the uneven demand all play into the total system that manufactures and distributes the 
influenza vaccine model each year.   
The Vaccine Model developed in this thesis looks at the problem of how to 
provide for the requests each year for the influenza vaccine during each annual influenza 
season.  Both the amount of customers requiring the vaccine or requesting it fluctuates.  
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The amount of vaccine to distribute to the customers each year also fluctuates due to 
problems relate to production.  Three out of the last five years in the United States there 
has been some manufacturing or contamination problem affecting the amount of 
vaccination doses that end up for distribution to the customers in the United States.  The 
Vaccine Model tries to identify the number of companies and the number of vaccine 
doses ordered per company that would be required to cover all the high-risk groups 
adequately if there was a problem in one or more of the companies licensed to provide 
the vaccine.  The Vaccine Model was also used to look at a pandemic situation and 
determine how much vaccine should be on hand to meet the potential customer demand. 
Other models in the past have included hospitalization costs to the total influenza 
season costs.  These costs are small when compared to costs incurred with each death.  
The hospitalization costs associated with those that get the influenza virus could add 
another one billion dollars to the total cost of the influenza pandemic.  The focus of this 
thesis is the costs associated with death each year from influenza and distribution of the 
influenza vaccine to minimize that cost. 
B. KEY POINTS AND RECOMMENDATIONS 
Each influenza season is different in severity and the number of customers 
seeking a vaccine.  A pandemic situation would add additional uncertainty to the 
problem.  Over the past few years, however, it is clear that not enough vaccine is being 
produced to cover the demand.  Only one out of the last four years has seen a surplus of 
vaccine after the conclusion of the influenza season.  
Although the rational method of architecting was used to develop a solution to the 
stated problem, a better approach would be the participative methodology (MAIER, 
2002) in which the complexities created by all the stakeholders were taken into account.  
The multiple stakeholders, including the companies that produce and distribute the 
influenza vaccine, need to agree on the overall system architecture instead of the 
fractured system in place today. 
 
  41
Four companies distributing the inactivated vaccine doses evenly could provide 
coverage for the population of the United States if a strict priority distribution policy is in 
place.  Distributing the vaccine without a priority would cause the amount of the vaccine 
required to increase significantly.   
A pandemic would require at minimum an order of around 208 million doses of 
vaccine spread over four companies to cover the United States population adequately if 
there was a 10% chance of contamination from each company.  This is based on the 
assumption of a strict priority distribution policy.  This is based on the assumption that a 
much higher percentage of people in each age group and category would be looking for 
the vaccine.  If the priority distribution is not used the number of vaccines required goes 
up to 300 million.   
The majority of the influenza seasons could be covered by purchasing fewer than 
108 million doses, as in the percentage distribution policy, making sure that the doses are 
spread out evenly over four companies and distributed by percentage but could be 
reduced to as little as 24.5 million doses if necessary using a strict priority distribution 
policy.  
Under the assumption that you can not enforce a strict priority for vaccine 
distribution, ordering around 26.89 million vaccine doses from four separate companies 
should reduce the effect of shortages in annual vaccine doses during a normal influenza 
season. 
C. VACCINE MODEL RESULTS 
The number of vaccinations given to customers in Scenario 1 and Scenario 3 for 
the Vaccine Model is based on a strict priority distribution policy.  Using four companies, 
the purchase of 24,335,875 influenza vaccine doses provides an average death total of 
44,985 and total cost of $34.6 billion in a normal influenza season if a strict order of 
vaccination is used.  This is Scenario 1 and Table 4-1.  The number of vaccinations given 
in Scenario 2 and Scenario 4 were based on percentage distribution policy.  Utilizing this 
policy, the amount of vaccine needed in a normal influenza year goes up to 107,572,140 
vaccine doses which provide a death toll of 43,631 at a cost of $35.5 billion dollars.  This 
is Scenario 2 and Table 4-2.   
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The result of not providing a large-scale immunization program based on the 
Vaccine Model developed would result in a cost of $41 billion and around 58,000 deaths 
during a normal influenza year as shown in Tables 4-1 and 4-2 when there are no good 
batches to use.   
 
Table 4-1. Scenario 1: Normal Influenza Season Cost in Billions, Priority 
Distribution policy, 44,985 Deaths 
 
Companies Average Cost all Good 1 Bad Batch 2 Bad Batches 3 Bad Batches 4 Bad Batches 
1   $ 35.26   $ 34.63   $ 41.01        
2   $ 34.72  $ 34.63   $ 34.80   $ 41.01      
3   $ 34.66   $ 34.63   $ 34.67   $ 35.15   $  41.01    
4   $ 34.64   $ 34.63   $ 34.60   $ 34.78   $  36.54   $ 41.01 
 
Table 4-2. Scenario 2: Normal Influenza Season Cost in Billions, Percentage 
Distribution policy, 43,631 Deaths 
 
Companies Average Cost All Good 1 Bad Batch 2 Bad Batches 3 Bad Batches 4 Bad Batches 
1  $ 36.12   $ 35.57  $ 41.01       
2  $ 35.89   $ 35.57  $ 37.05   $ 41.01     
3  $ 35.69  $ 35.57  $ 35.73   $ 38.37   $ 41.01   
4  $ 35.51   $ 35.57   $ 35.07   $ 37.05   $ 39.20   $41.01 
 
D. PANDEMIC SITUATION 
If the normal influenza season turned into a pandemic situation there are several 
options for reducing the loss of life.  One of those is not producing more inactivated 
vaccine.  In the past during a shortage situation or a pandemic the amount of vaccine on 
hand was distributed to those who were thought to have the most risk of death, not by 
how much value they would add in the future to the economy or society.  If a pandemic 
occurs under the current production process there would most likely be a shortage 
situation due to the fact that most of the population would seek out a vaccination if it was 
available.  The pandemic influenza is modeled using a 35% attack rate.  Nobody can 
predict the attack rate of a future pandemic but it is estimate that it would be higher than a 
normal influenza season (MELTZER, 1999).  That scenario would double or even triple 
the current requests for vaccinations.  The assumption used is that 80% of the population 
will search for a vaccination, or an estimated 225.1 million customers.  A priority must be 
identified and followed for either shortage situation, production difficulties or a 
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pandemic.  The distribution must also be made under the current system at least at first 
until other more drastic government regulations are put into place or technology progress 
makes the manufacturing process adaptive.  
With four companies and a strict priority distribution into a pandemic situation 
where 80% of the population would be looking for a vaccine the amount of vaccine to be 
purchased would be 208,340,603 providing an average death toll of 54,798 using four 
companies at a cost of $41.36 billion.  This is Scenario 3 and Table 4-3.  If you had all 
the vaccine that you needed for all the customers that wanted a vaccine you could save 
more lives.  Using a percentage distribution policy 300,181,334 vaccine doses would be 
needed to cover the amount of customers that would come in for a vaccine estimated at 
$225.14 million.  Based on the Vaccine Model calculations and using four companies 
you would order 52,085,150 doses from each of the four companies in a pandemic 
situation using the strict priority distribution policy.   
Using the percentage distribution policy in the Vaccine Model calculations and 
using four companies you would order 75,045,334 from each of the four companies in a 
pandemic situation.  A total of 300,181,334 vaccine doses would need to be ordered to 
cover the amount of customers that would come in for a vaccine.  Using four companies, 
there would be 53,400 deaths at a cost of $43.01 billion dollars.  This is Scenario 4 and 
Table 4-4. 
Meltzer (1999) estimated that at a minimum the cost to the United States 
economy of an influenza pandemic would be around $71 billion without a large-scale 
immunization.  The Vaccine Model presented in this thesis estimates a cost of $71.8 
billion cost to the United States economy without an immunization program. 
 
Table 4-3. Scenario 3: Pandemic Influenza Season Cost in Billions, Priority 
Distribution, 54,798 Deaths 
 
Companies Average Cost All Good 1 Bad Batch 2 Bad Batches 3 Bad Batches 4 Bad Batches 
1  $ 44.39   $ 41.35   $ 71.77        
2  $ 41.66  $ 41.35   $ 41.38   $ 71.77      
3  $ 41.39   $ 41.35   $ 41.37   $ 41.57   $ 71.77    
4  $ 41.36   $ 41.35  $ 41.36   $ 41.38   $ 42.03   $ 71.77 
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Table 4-4. Scenario 4: Pandemic Influenza Season Cost in Billions, Percentage 
Distribution, 53,400 Deaths 
 
Companies Average Cost All Good 1 Bad Batch 2 Bad Batches 3 Bad Batches 4 Bad Batches 
1  $ 45.81   $ 42.92   $71.77       
2  $ 44.78   $ 42.92   $51.60  $ 71.77      
3  $ 43.85   $ 42.92   $44.88   $ 58.33  $ 71.77    
4  $ 43.01  $ 42.92   $41.52   $ 51.60   $ 62.15  $71.77 
 
E. POTENTIAL AREAS TO CONDUCT FURTHER RESEARCH 
Additional studies could be done to research particular company probability rates 
for contamination and develop the Vaccine Model to add specific companies and 
contamination probabilities for a more accurate assessment.  A study could be done on 
how the percentages would change in each age category during a pandemic.  A better 
definition of economic loss for each age group could also be developed instead of just 
two categories of over 65 years old and under 65 years old.  Besides the overall 
estimation that all categories would be increasing requests for vaccines, the question of 
exactly how the percentages would change for each category and what that would mean 
for health care providers could be researched.  
F. CHAPTER SUMMARY 
By CDC calculation, 185 million doses should be available each year to make 
sure an adequate supply gets to those customers who should be getting that vaccine.  The 
Vaccine Model estimates that around 108 million on an average year are needed to 
minimize cost to the economy and loss of life.  Each year the vaccination number 
produced for the influenza virus is limited and never reached 185 million.  One of the 
distribution strategies was a strict distribution policy where the identified priority 
customers get the vaccine first.  The other distribution strategy that was used was a 
percentage distribution policy that was based on distributing the vaccine as the population 
requested it.  The percentage distribution policy is closer to a real life situation in that you 
usually get a percentage mix of high risk and low risk customers.  If the cost of life is 
changed and made equal for the normal influenza season with priority distribution then 
the total cost of the program increases to $45.23 billion from $34.64 billion with an 
additional 12 million vaccine doses required to minimize total cost.  The Vaccine Model 
found that four companies can adequately produce the vaccine required even if one of the 
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companies fails.  Using the percentage distribution policy no shortage would occur unless 
more than one company failed to produce the requested vaccination doses.  The strict 
distribution policy reduces the amount of vaccine doses required by under a third of that 
required using the percentage distribution policy in a normal influenza year.   
The total cost of the vaccine program under the strict priority distribution policy 
would be $34.6 billion for a normal vaccination year to $41.36 billion for a pandemic 
year.  Minimum cost and loss of life in a pandemic situation would be accomplished if a 
strict priority distribution policy was used.  Under shortage conditions, the risk of not 
being able to cover all customers in a pandemic situation is minimized by using the strict 
distribution policy and a decrease in overall cost of $1.7 billion dollars versus the 
percentage distribution policy with around 208 million doses ordered.  The use of a strict 
priority distribution in a shortage situation limits loss of life to an average additional 
1,300 United States citizens under a pandemic situation if the production of vaccine is 
spread over four companies.  Actual vaccine costs are reduced by over $1 billion dollars 
during a normal influenza season and over $600 million during a pandemic year by using 
the strict priority distribution.   
The result of not providing a large-scale immunization program based on the 
Vaccine Model developed would result in a cost of $41 billion and around 58,000 deaths 
during a normal influenza year based on the results of the Vaccine Model.  No vaccine 
immunization program during a pandemic would result in an economic loss of $71.8 
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